Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer
Cohen, E.E.W., Licitra, L.F., Burtness, B., Fayette, J., Gauler, T., Clement, P.M., Grau, J.J., del Campo, J.M., Mailliez, A., Haddad, R.I., Vermorken, J.B., Tahara, M., Guigay, J., Geoffrois, L., Merlano, M.C., Dupuis, N., Krämer, N., Cong, X.J., Gibson, N., Solca, F., Ehrnrooth, E., Machiels, J.-P.H.
Published in Annals of oncology (01.10.2017)
Published in Annals of oncology (01.10.2017)
Get full text
Journal Article
314O_PR Second-line afatinib vs methotrexate (MTX) in patients (pts) with recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC): subgroup/biomarker analysis of LUX-head and neck 1 (LUX-H&N1)
Tahara, M., Cohen, E.E.W., Haddad, R.I., Fayette, J., Licitra, L.F., Clement, P.M., Vermorken, J.B., Gauler, T., Cupissol, D., Grau, J.J., Guigay, J., del Campo, J.M., Okami, K., Takahashi, S., Burtness, B., Cong, X.J., Gibson, N., Solca, F., Ehrnrooth, E., Machiels, J.-P.H.
Published in Annals of oncology (01.12.2015)
Published in Annals of oncology (01.12.2015)
Get full text
Journal Article